Natural and synthetic α,β-unsaturated carbonyls for NF-κB inhibition

Future Medicinal Chemistry

Volumn 1, Issue 1, 2009, Pages 179-200

  Ramachandran, P Veeraraghavan ^a   Yip Schneider, Michele ^b   Schmidt, C Max ^b,c,d  

^a PURDUE UNIVERSITY   (United States)

^b INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETIC ACID DERIVATIVE; ALPHA ALKYLIDENE BUTYROLACTONE; ALPHA ALKYLIDENE GAMMA BUTYROLACTONE; ALPHA ALKYLIDENE GAMMA BUTYROLACTONE DERIVATIVE; ALPHA METHYLENE BUTYROLACTONE; BORONIC ACID DERIVATIVE; CAFFEIC ACID DERIVATIVE; CAFFEIC ACID ESTER DERIVATIVE; CARBONYL DERIVATIVE; CROTYLBORONATE DERIVATIVE; ENONE DERIVATIVE; FLAVONOID; HEDYCHILACTONE B; HYDROXYSTILBENE DERIVATIVE; I KAPPA B; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LACTONE DERIVATIVE; LEWIS ACID; MONOACETATE DERIVATIVE; QUINONE DERIVATIVE; SESQUITERPENE LACTONE DERIVATIVE; STEROID; STILBENE DERIVATIVE; THIOL; UNCLASSIFIED DRUG;

CARCINOGENESIS; CATALYSIS; CHEMICAL STRUCTURE; CYCLIZATION; NEOPLASM; PRIORITY JOURNAL; PROTEIN FUNCTION; REACTION ANALYSIS; SHORT SURVEY; STRUCTURE ANALYSIS; SUBSTITUTION REACTION; SYNTHESIS;

CAFFEIC ACIDS; FLAVONOIDS; NF-KAPPA B; QUINONES; SESQUITERPENES; STILBENES;

EID: 77953460179     PISSN: 17568919     EISSN: None     Source Type: Journal    
DOI: 10.4155/fmc.09.15     Document Type: Short Survey

References (130)

1. Sen R, Baltimore D. Inducibility of k immunoglobulin enhancer-binding protein NF-kB by a posttranslational mechanism. Cell 47(6), 921-928 (1986).
2. Delhalle, S, Blasius R, Dicato M, Diederich M. A beginner's guide to NFkB signaling pathways. Ann. N. Y. Acad. Sci. 1030, 1-13 (2004).
3. Ghosh S. Handbook of Transcription Factor NF-kB. Sankar Ghosh (Ed.). Taylor and Francis CRC Press, Boca Raton, FL, USA (2007).
4. Gilmore TD (Ed). Special issue on NF-kB. Oncogene 25, 6679-6899 (2006).
5. Chariot A. 20 years of NF-kB. Biochem. Pharmacol. 72(9), 1051-1053 (2006).
6. Brennan P, Donev R, Hewamana S. Targeting transcription factors for therapeutic benefit. Mol. Biosyst. 4(9), 909-919 (2008).
7. Karin M, Yamamoto Y, Wang QM. The IKK NF-kB system: a treasure trove for drug development. Nature Rev. Drug Discovery 3, 17-26 (2004).
8. Pande V, Ramos MJ. NF-kB in human disease: current inhibitors and prospects for I structure based design of inhibitors. Current Med. Chem. 12, 357-374 (2005).
9. O'Shea JM, Perkins ND. Regulation of the RelA (p65) transactivation domain. Biochem. Soc. Trans. 36(4), 603-608 (2008)
10. Wong ET, Tergaonkar V. Roles of NF-kB in health and disease: mechanisms and therapeutic potential. Clin. Sci. 116(5-6), 451-465 (2009).
11. Nam NH. Naturally occurring NF-kB inhibitors. Mini Rev. Med. Chem. 6(8), 945-951 (2006).
12. Ghosh S, Hayden MS. New regulators of NF-kB in inflammation. Nat. Reviews Immun. 8 (11), 837-848 (2008).
13. Grey ST. Regulating inflammation: the ying and yang of NF-kB activation. Immun. Cell. Biol. 86, 299-300 (2008).
14. Folmer F, Schumacher M, Diederich M, Jaspars M. Finding NEMO (inhibitors) the search for marine pharmacophores targeting the nuclear factor-kB. Chemistry Today 26(4), 40-46 (2008).
15. Liu J, Yoshida Y, Yamashita U. DNA-binding activity of NF-kB and phosphorylation of p65 are induced by N-acetylcysteine through phosphatidylinositol (PI) 3-kinase. Mol. Immunol. 45(15), 3984-3989 (2008).
16. Poole LB, Nelson KJ. Discovering mechanisms of signaling-mediated cysteine oxidation. Current Opin. Chem. Biol. 12, 18-24 (2008).
17. Kawauchi K, Araki K, Tobiume K, Tanaka N. p53 regulates glucose metabolism through an IKK-NF-kB pathway and inhibits cell transformation. Nature Cell Biol. 10(5), 611-618 (2008).
18. Adcock IM, Ito K, Barnes PJ. Glucocorticoids: effects on gene transcription. Proc. Am. Thorac. Soc. 1(3), 247-254 (2004).
19. Hoffmann HMR, Rabe J. Synthesis and biological-activity of a-methylene-gbutyrolactones. Angew. Chem. Int. Ed. Engl. 24 (2), 94-110 (1985).
20. Ghosh S, May MJ, Kopp EB. NF-kB and Rel proteins: evolutionarily conserved mediators of immune responses. Annu. Rev. Immunol. 16, 225-260 (1998).
21. Baldwin AS Jr. The NF-k B and IkB proteins: new discoveries and insights. Annu. Rev. Immunol.14, 649-683 (1996).
22. Holcomb B, Yip-Schneider M, Schmidt CM. The role of nuclear factor kB in pancreatic cancer and the clinical applications of targeted therapy. Pancreas 36(3), 225-235 (2008).
23. Viatour P, Merville MP, Bours V, Chariot A. Phosphorylation of NF-kB and IkB proteins: implications in cancer and inflammation. Trends Biochem. Sci. 30(1), 43-52 (2005).
24. Gyrd-Hansen M, Darding M, Miasari M et al. IAPs contain an evolutionarily conserved ubiquitin-binding domain that regulates NF-kB as well as cell survival and oncogenesis. Nat. Cell Biol. 10(11), 1309-1317 (2008).
25. Zarnegar B, Yamazaki S, He JQ, Cheng G. Control of canonical NF-kB activation through the NIK-IKK complex pathway. Proc. Natl Acad. Sci. USA 105(9), 3503-3508 (2008).
26. Wallach D, Kovalenko A. Self-termination of the terminator. Nat. Immunol. 9(12), 1325-1327 (2008).
27. Kawauchi K, Araki K, Tobiume K, Tanaka N. Activated p53 induces NF-kB DNA binding but suppresses its transcriptional activation. Biochem. Biophy. Res. Comm. 372, 137-141 (2008).
28. Baldwin AS Jr. Series introduction: the transcription factor NF-kB and human disease. J. Clin. Invest. 107(1), 3-6 (2001).
29. Kim HJ, Hawke N, Baldwin AS. NF-kB and IKK as therapeutic targets in cancer. Cell Death Differ. 13(5), 738-747 (2006).
30. Satoh T, Okamoto SI, Cui J et al. Activation of the Keap1/Nrf2 pathway for neuroprotection by electrophilic Phase II inducers. Proc. Natl Acad. Sci. USA 103(3), 768-773 (2006).
31. Lau A, Villeneuve NF, Sun Z, Wong PK, Zhang DD. Dual roles of Nrf2 in cancer. Pharmacol. Res. 58, 262-270 (2008).
32. Fitzpatrick B, Mehibel M, Cowen RL, Stratford IJ. iNOS as a therapeutic target for treatment of human tumors. Nitric Oxide 19, 217-224 (2008).
33. Xie QW, Kashiwabara Y, Nathan C. Role of transcription factor NF-k B/Rel in induction of nitric oxide synthase. J. Biol. Chem. 269, 4705-4708 (1994).
34. Copple IM, Goldring CE, Kitteringham NR, Park BK. The Nrf2-Keap1 defence pathway: role in protection against drug-induced toxicity. Toxicology 246, 24-33 (2008).
35. Scapagnini G, Foresti R, Calabrese V, Giuffrida Stella AM, Green CJ, Motterlini R. Caffeic acid phenethyl ester and curcumin: a novel class of heme oxygenase-1 inducers. Mol. Pharmacol. 61(3), 554-561 (2002).
36. Sethi G, Sung B, Aggarwal BB. Nuclear factor-kB activation: from bench to bedside. Exp. Biol. Med. (Maywood) 233(1), 21-31 (2008).
37. Guttridge DC, Albanese C, Reuther JY, Pestell RG, Baldwin AS Jr. NF-kB controls cell growth and differentiation through transcriptional regulation of cyclin D1. Mol. Cell. Biol. 19, 5785-5799 (1999).
38. Nakanishi C, Toi M. Nuclear factor-kB inhibitors as sensitizers to anticancer drugs. Nat. Rev. Cancer 5(4), 297-309 (2005).
39. Arlt A, Gehrz A, Muerkoster S, Vorndamm J, Kruse ML, Folsch UR, Schafer H. Role of NF-kB and Akt/PI3K in the resistance of pancreatic carcinoma cell lines against gemcitabine-induced cell death. Oncogene 22(21), 3243-3251 (2003).
40. Arlt A, Vorndamm J, Breitenbroich M et al. Inhibition of NF-kB sensitizes human pancreatic carcinoma cells to apoptosis induced by etoposide (VP16) or doxorubicin. Oncogene 20(7), 859-868 (2001).
41. Bednarski BK, Ding X, Coombe K, Baldwin AS, Kim HJ. Active roles for inhibitory kB kinases a and b in nuclear factor-kBmediated chemoresistance to doxorubicin. Mol. Cancer Ther. 7(7), 1827-1835 (2008).
42. Mi J, Zhang X, Rabbani ZN et al. RNA aptamer-targeted inhibition of NF-kB suppresses non-small cell lung cancer resistance to doxorubicin. Mol. Ther. 16, 66-73 (2008).
43. Salminen A, Lehtonen M, Suuronen T, Kaarniranta K, Huuskonen J. Terpenoids: natural inhibitors of NF-kB signaling with anti-inflammatory and anticancer potential. Cell. Mol. Life Sci. 65(19), 2979-2999 (2008).
44. Aggarwal BB, Shishodia S. Suppression of nuclear factor-k B activation pathway by spice-derived phytochemicals: reasoning for seasoning. Ann. N. Y. Acad. Sci. 1030, 434-441 (2004).
45. Folmer F, Jaspars M, Dicato M, Diederich M. Marine natural products as targeted modulators of the transcription factor NF-kB. Biochem. Pharmacol. 75, 603-617 (2008).
46. Gilmore TD, Herscovitch M. Inhibitors of NF-kB signaling: 785 and counting. Oncogene 25, 6887-6899 (2006)
47. Sun SC, Ley SC. New insights into NF-kB regulation and function. Trends Immun. 29(10), 469-478 (2008).
48. Kupchan SM, Fessler DC, Eakin MA, Giacobbe TJ. Reactions of a-methylene lactone tumor inhibitors with model biological nucleophiles. Science 168 (3929), 376-378 (1970).
49. Holland R, Hawkins AE, Eggler AL, Mesecar AD, Fabris D, Fishbein JC. Prospective Type 1 and Type 2 disulfides of keap1 protein. Chem. Res. Toxicol. 21, 2051-2060 (2008).
50. Chiang YM, Lo CP, Chen YP et al. Ethyl caffeate suppresses NF-kB activation and its downstream inflammatory mediators, iNOS, COX-2, and PGE2 in vitro or in mouse skin. Br. J. Pharmacol. 146(3), 352-363 (2005).
51. Natarajan K, Singh S, Burke TR Jr, Grunberger D, Aggarwal BB. Caffeic acid phenethyl ester is a potent and specific inhibitor of activation of nuclear transcription factor NFkB. Proc. Natl Acad. Sci. USA 93(17), 9090-9095 (1996).
52. Scapagnini G, Foresti R, Calabrese V, Giuffrida Stella AM, Green CJ, Motterlini R. Caffeic acid phenethyl ester and curcumin: a novel class of heme oxygenase-1 inducers. Mol. Pharmacol. 61(3), 554-561 (2002).
53. Cleland WW. Dithiothreitol, a new protective reagent for SH groups. Biochemistry 3, 480-482 (1964).
54. Sethi G, Ahn KS, Aggarwal BB. Targeting nuclear factor-kB activation pathway by thymoquinone: role in suppression of anti-apoptotic gene products and enhancement of apoptosis. Mol. Cancer Res. 6(6), 1059-1070 (2008).
55. El Gazzar MA, El Mezayen R, Nicolls MR, Dreskin SC. Thymoquinone attenuates proinflammatory responses in lipopolysaccharide-activated mast cells by modulating NF-kB nuclear transactivation. Biochim. Biophys. Acta 1770, 556-564 (2007).
56. Sandur SK, Ichikawa H, Sethi G, Ahn KS, Aggarwal BB. Plumbagin (5-hydroxy-2- methyl-1,4-naphthoquinone) suppresses NF-kB activation and NF-kB-regulated gene products through modulation of p65 and IkBa kinase activation, leading to potentiation of apoptosis induced by cytokine and chemotherapeutic agents. Biol. Chem. 281(25), 17023-17033 (2006).
57. Ahmad A, Banerjee S, Wang Z, Kong D, Sarkar FH. Plumbagin-induced apoptosis of human breast cancer cells is mediated by inactivation of NF-kB and Bcl-2. J. Cell Biochem. 105(6), 1461-1471 (2008).
58. Dhillon N, Aggarwal BB, Newman RA et al. Phase II trial of curcumin in patients with advanced pancreatic cancer. Clin. Cancer Res. 14(14), 4491-4499 (2008).
59. Hatchera H, Planalpb R, Chob J, Tortia FM, Tortic SV. Curcumin: from ancient medicine to current clinical trials. Cell. Mol. Life Sci. 65, 1631-1652 (2008).
60. Aggarwal S, Ichikawa H, Takada Y, Sandur SK, Shishodia S, Aggarwal BB. Curcumin (diferuloylmethane) down-regulates expression of cell proliferation and anti-apoptotic and metastatic gene products through suppression of IkBa kinase and Akt activation. Mol. Pharmacol. 69(1), 195-206 (2006).
61. Balogun E, Hoque M, Gong P et al. Curcumin activates the haem oxygenase-1 gene via regulation of Nrf2 and the antioxidant-responsive element. Biochem J. 371(3), 887-895 (2003).
62. Woo HB, Shin WS, Leed S, Ahn CM. Synthesis of novel curcumin mimics with asymmetrical units and their anti-angiogenic activity. Bioorg. Med. Chem. Lett. 15, 3782-3786 (2005).
63. Amolins MW, Peterson LB, Blagg BS. Synthesis and evaluation of electron-rich curcumin analogues. Bioorg. Med. Chem. 17(1), 360-367 (2009).
64. Alcaraz MJ, Vicente AM, Araico A, Dominguez JN, Terencio MC, Ferrándiz ML. Role of nuclear factor-kB and heme oxygenase-1 in the mechanism of action of an anti inflammatory chalcone derivative in RAW 264.7 cells. Br. J. Pharmacol. 142(7), 1191-1199 (2004).
65. Madan B, Batra S, Ghosh B. 2́-hydroxychalcone inhibits nuclear factor-kB and blocks tumor necrosis factor-a- and lipopolysaccharide-induced adhesion of neutrophils to human umbilical vein endothelial cells. Mol. Pharmacol. 58, 526-534 (2000).
66. Ban HS, Suzuki K, Lim SS et al. Inhibition of lipopolysaccharide-induced expression of inducible nitric oxide synthase and tumor necrosis factor-a by 2́-hydroxychalcone derivatives in RAW 264.7 cells. Biochem. Pharmacol. 67, 1549-1557 (2004).
67. Lee JH, Jung HS, Giang PM et al. Blockade of nuclear factor-kB signaling pathway and anti-inflammatory activity of cardamomin, a chalcone analog from Alpinia conchigera. J. Pharmacol. Exp. Ther. 316(1), 271-278 (2006).
68. Israf DA, Khaizurin TA, Syahida A, Lajis NH, Khozirah S. Cardamonin inhibits COX and iNOS expression via inhibition of p65NF-kB nuclear translocation and Ik-B phosphorylation in RAW 264.7 macrophage cells. Mol. Immunol. 44(5), 673-679 (2007).
69. Pandey MK, Sandur SK, Sung B, Sethi G, Kunnumakkara AB, Aggarwal BB. Butein, a tetrahydroxychalcone, inhibits nuclear factor (NF)-kB and NF-kB-regulated gene expression through direct inhibition of IkB kinase b on cysteine-179 residue. J. Biol. Chem. 282(24), 17340-17350 (2007).
70. Dinkova-Kostova AT, Massiah MA, Bozak RE, Hicks RJ, Talalay P. Potency of Michael reaction acceptors as inducers of enzymes that protect against carcinogenesis depends on their reactivity with sulfhydryl groups. Proc. Natl Acad. Sci. USA. 98(6), 3404-3409 (2001).
71. Dong Z. Molecular mechanism of the chemopreventive effect of resveratrol. Mutation Res. 523-524, 145-150 (2003).
72. Cerny D, Canová NK, Martínek J et al. Effects of resveratrol pretreatment on tert-butylhydroperoxide induced hepatocyte toxicity in immobilized perifused hepatocytes: involvement of inducible nitric oxide synthase and hemoxygenase-1. Nitric Oxide 20, 1-8 (2009).
73. Bensasson RV, Zoete V, Dinkova-Kostova AT, Talalay P. Two-step mechanism of induction of the gene expression of a prototypic cancer-protective enzyme by diphenols. Chem. Res. Toxicol. 21(4), 805-812 (2008).
74. Ramasamy K, Agarwal R. Multitargeted therapy of cancer by silymarin. Cancer Letters 269(2), 352-362 (2008).
75. Davis JN, Kucuk O, Sarkar FH. Genistein inhibits NF-kB activation in prostate cancer cells. Nutrition Cancer 35 (2), 167-174 (1999).
76. Hämäläinen M, Nieminen R, Vuorela P, Heinonen M, Moilanen E. Anti-inflammatory effects of flavonoids: genistein, kaempferol, quercetin, and daidzein inhibit STAT-1 and NF-kB activations, whereas flavone, isorhamnetin, naringenin, and pelargonidin inhibit only NF-kB activation along with their inhibitory effect on iNOS expression and NO production in activated macrophages. Mediators Inflamm. 45673 (2007).
77. Appendino G, Maxia L, Bascope M et al. A meroterpenoid NF-kB inhibitor and drimane sesquiterpenoids from Asafetida. J. Nat. Prod. 69 (7), 1101-1104 (2006).
78. Malara N, Focà D, Casadonte F et al. Simultaneous inhibition of the constitutively activated nuclear factor kB and of the interleukin-6 pathways is necessary and sufficient to completely overcome apoptosis resistance of human U266 myeloma cells. Cell Cycle 7(20), 3235-3245 (2008).
79. Oh JH, Lee TJ, Park JW, Kwon TK. Withaferin A inhibits iNOS expression and nitric oxide production by Akt inactivation and down-regulating LPS-induced activity of NF-kB in RAW 264.7 cells. Eur. J. Pharmacol. 599(1-3), 11-17 (2008).
80. Kaileh M, Vanden Berghe W, Heyerick A et al. Withaferin A strongly elicits IkB kinase b hyperphosphorylation concomitant with potent inhibition of its kinase activity. J. Biol. Chem. 282(7), 4253-4264 (2007).
81. Ichikawa H, Aggarwal BB. Guggulsterone inhibits osteoclastogenesis induced by receptor activator of nuclear factor-kB ligand and by tumor cells by suppressing nuclear factor-kB activation. Clin. Cancer Res. 12(2), 662-668 (2006).
82. Shishodia S, Aggarwal BB. Guggulsterone inhibits NFkB and IkBa kinase activation, suppresses expression of anti-apoptotic gene products, and enhances apoptosis. J. Biol. Chem. 279 (45), 47148-147145 (2004).
83. Yoshioka H, Mabre TJ, Timmermann BN. Sesquiterpene Lactones. University of Tokoyo Press, Tokyo, Japan (1973).
84. Siedle B, García-Piñeres AJ, Murillo R et al. Quantitative structure-activity relationship of sesquiterpene lactones as inhibitors of the transcription factor NF-kB. J. Med. Chem. 47(24), 6042-6054 (2004).
85. Rüngeler P, Castro V, Mora G et al. Inhibition of transcription factor NF-kB by sesquiterpene lactones: a proposed molecular mechanism of action. Bioorg. Med. Chem. 7, 2343-2352 (1999).
86. García-Pineres AJ, Castro V, Mora G et al. Cysteine 38 in p65/NF-kB plays a crucial role in DNA binding inhibition by sesquiterpene lactones. J. Biol. Chem. 276(43), 39713-39720 (2002).
87. Patel NM, Nozaki, S, Shortle NH et al. Paclitaxel sensitivity of breast cancer cells with constitutively active NF-kB is enhanced by IkBa super-repressor and parthenolide. Oncogene 19, 4159-4169 (2000).
88. Kwok BH, Koh B, Ndubuisi MI, Elofsson M, Crews CM. The anti-inflammatory natural product parthenolide from the medicinal herb Feverfew directly binds to and inhibits IkB kinase. Chem. Biol. 8(8), 759-766 (2001).
89. Hehner SP, Hofmann TG, Droge W, Schmitz ML. The anti-inflammatory sesquiterpene lactone parthenolide inhibits NF-kB by targeting the I k B kinase complex. J. Immunol. 163, 5617-5623(1999).
90. Koo TH, Lee JH, Park YJ et al. A sesquiterpene lactone, costunolide, from Magnolia grandiflora inhibits NF-kB by targeting IkB phosphorylation. Planta Med. 67, 103-107 (2001).
91. Pae HO, Jeong GS, Kim HS et al. Costunolide inhibits production of tumor necrosis factor-a and interleukin-6 by inducing heme oxygenase-1 in RAW264.7 macrophages. Inflamm. Res. 56(12), 520-526 (2007).
92. Lyss G, Knorre A, Schmidt TJ, Pahl HL, Merfort I. The anti-inflammatory sesquiterpene lactone helenalin inhibits the transcription factor NF-kB by directly targeting p65. J. Biol. Chem. 273(50), 33508-33516 (1998).
93. Umemura K, Itoh T, Hamada N et al. Preconditioning by sesquiterpene lactone enhances H2O2-induced Nrf2/ARE activation. Biochem. Biophys. Res. Commun. 368(4), 948-954 (2008).
94. Lee KH, Furukawa H. Antitumor agents. 3. Synthesis and cytotoxic activity of helenalin amine adducts and related derivatives. J. Med. Chem. 15(6), 609-611 (1972).
95. Hejchman E, Haugwitz RD, Cushman M. Synthesis and cytotoxicity of water-soluble ambrosin prodrug candidates. J. Med. Chem. 38(17), 3407-3410 (1995).
96. Nasim S, Crooks PA. Antileukemic activity of aminoparthenolide analogs. Bioorg. Med. Chem. Lett. 18, 3870-3873 (2008).
97. Grieco PA. Methods for the synthesis of a-methylene lactones. Synthesis (2), 67-72 (1975).
98. Howie GA, Manni PE, Cassady JM. Synthesis of alkyl-substituted a,bunsaturated g-lactones as potential antitumor agents. J. Med. Chem. 17(8), 840-843 (1974).
99. Parsons AF, Pettifer RM. Synthesis of hydroxy pyrrolidines and piperidines via free-radical cyclisations. J. Chem. Soc. Perkin Trans. I (4), 651-660 (1998).
100. Jung ME, Murakami M. Total synthesis of (+/-)-hedychilactone B: stepwise allenoate diene cycloaddition to prepare trimethyldecalin systems. Org. Lett. 9(3), 461-463 (2007).
101. Lee K, Jackson JA, Wiemer DF. Stereocontrol in Horner-Wadsworth-Emmons condensations of a-phosphono lactones with aldehydes - a synthesis of integerrinecic acid and senecic acid lactones. J. Org. Chem. 58(22), 5967-5971 (1993).
102. Piers E, Wai JSM. Total synthesis of the ent-clerodane diterpenoids (+/-)-isolinaridiol and (+/-)-isolinaridiol diacetate. J. Chem. Soc. Chem. Commun. (18), 1245-1247 (1988).
103. Tanaka K, Tamura N, Kaji A. A simple, stereocontrolled synthesis of a-alkylidene-gbutyrolactones. Chem. Lett. 5, 595-598 (1980).
104. Murray AW, Reid RG. A new synthesis of a-methylene lactones. J. Chem. Soc. Chem. Commun. (2), 132-133 (1984).
105. Larson GL, Deperez RMB. The chemistry of a-silyl carbonyl-compounds .10. A 2-step preparation of a-alkylidene g-lactones from g-lactones - a synthesis of (+/-)-ancepsenolide. J. Org. Chem. 50(25), 5257-5260 (1985).
106. Bachi MD, Bosch E. Synthesis of g-lactones and d-lactones by free-radical annelation of se-phenyl selenocarbonates. J. Org. Chem. 57(17), 4696-4705 (1992).
107. Bellina F, Carpita A, Desantis M, Rossi R. Synthesis of variously 2-substituted alkyl (Z)-2-alkenoate and (E)-2-alkenoate and (Z)-a-ylidene-g- butyrolactone and (E)-a-ylidene-g-butyrolactone via palladiummediated cross-coupling reactions between organostannanes and organic halides. Tetrahedron 50(41), 12029-12046 (1994).
108. Forbes JE, Zard SZ. New radical chainreaction of S-alkoxycarbonyl dithiocarbonates - a useful source of alkyl radicals from alcohols. J. Am. Chem. Soc. 112(5), 2034-2036 (1990).
109. Okamoto S, Kasatkin A, Zubaidha PK, Sato F. Intramolecular nucleophilic acyl substitution reactions mediated by XTi(O-i-Pr)(3) (X=Cl, O-i-Pr)/2i-PrMgBr reagent. Efficient synthesis of functionalized organotitanium compounds from unsaturated compounds. J. Am. Chem. Soc. 118(9), 2208-2216 (1996).
110. Eklund PC, Sjoholm RE. Oxidative transformation of the natural lignan hydroxymatairesinol with 2,3-dichloro-5,6- dicyano-1,4-benzoquinone. Tetrahedron 59(25), 4515-4523 (2003).
111. Jang HY, Hughes FW, Gong HG, Zhang JM, Brodbelt JS, Krische MJ. Enantioselective reductive cyclization of 1,6-enynes via rhodium-catalyzed asymmetric hydrogenation: C-C bond formation precedes hydrogen activation. J. Am. Chem. Soc. 127(17), 6174-6175 (2005).
112. Robertson J, Menard M, Ford R, Bell S. Conjugate addition of organocopper reagents to g-alkoxybutenolides and application to the synthesis of non-racemic alkyl cyclopentenones. Org. Biomol. Chem. 2(20), 2988-2997 (2004).
113. Bella M, Piancatelli G, Pigro MC. 3-phenylselanylfuran-2(5H)-one: a versatile building block in the synthesis of lignans. A new approach towards 3,4-dibenzyl g-butyrolactones. Tetrahedron 55(42), 12387 (1999).
114. Fleming I, Goldhill J. B-silylcarbonyl compounds as masked enones. J. Chem. Soc. Perkin Trans. 1(7), 1493-1498 (1980).
115. Moïse J, Arseniyadis S, Cossy J. Crossmetathesis between a-methylene-gbutyrolactone and olefins: a dramatic additive effect. Org. Lett. 9(9), 1695-1698 (2007).
116. Raju R, Allen LJ, Le T, Taylor CD, Howell AR. Cross metathesis of a-methylene lactones II: g- and d-lactones. Org. Lett. 9(9), 1699-1701 (2007).
117. Chataigner I, Lebreton J, Zammattio F, Villieras J. Asymmetric synthesis using a new chiral b-functionalized allylboronate derived from endo-2-phenyl-exo-2,3-bornanediol: preparation and reactions with aldehydes. Tetrahedron Lett. 38(21), 3719-3722 (1997).
118. Elford TG, Arimura Y, Yu SH, Hall DG. Triflic acid-catalyzed additions of 2-alkoxycarbonyl allylboronates to aldehydes. Study of scope and mechanistic investigation of the reaction stereochemistry. J. Org. Chem. 72(4), 1276-1284 (2007).
119. Drewes SE, Roos GHP. Synthetic potential of the tertiary-amine-catalysed reaction of activated vinyl carbanions with aldehydes. Tetrahedron 44(15), 4653-4670 (1988).
120. Basavaiah D, Rao PD, Hyma RS. The Baylis-Hillman reaction: a novel carbon- carbon bond forming reaction. Tetrahedron 52(24) 8001-8062 (1996).
121. Basavaiah D, Rao AJ, Satyanarayana T. Recent advances in the Baylis-Hillman reaction and applications. Chem. Rev. 103(3), 811-891 (2003).
122. Ramachandran PV, Pratihar D, Biswas D, Srivastava A, Ram Reddy MV. Novel functionalized trisubstituted allylboronates via Hosomi-Miyaura borylation of functionalized allyl acetates. Org. Lett. 6(4), 481-484 (2004).
123. Kabalka GW, Venkataiah B, Dong G. Pd-catalyzed cross-coupling of Baylis- Hillman acetate adducts with bis(pinacolato)diboron: an efficient route to functionalized allyl borates. J. Org. Chem. 69(17), 5807-5809 (2004).
124. Ramachandran PV, Pratihar D, Biswas D. Control of stereochemistry: a general synthesis of cis- or trans-b,g-disubstituted-gbutyrolactones following Z-crotylboration. Org. Lett. 8(17), 3877-3879 (2006).
125. Ramachandran PV, Pratihar D. Aciditydirected synthesis of substituted g-butyrolactones from aliphatic aldehydes. Org, Lett. 9(11), 2087-2090 (2007).
126. Ramachandran PV, Garner G, Pratihar D. Synthesis of E- and Z-a-alkylidene-g-aryl-gbutyrolactones via alkenylalumination of oxiranes. Org, Lett. 9(23), 4753-4756 (2007).
127. Baud V, Karin M. Is NF-kB a good target for cancer therapy? Hopes and pitfalls. Nat. Rev. Drug Discov. 8(1), 33-40 (2009).
128. Sakurai T, Maeda S, Chang L, Karin M. Loss of hepatic NF-kB activity enhances chemical hepatocarcinogenesis through sustained c-Jun N-terminal kinase 1 activation. Proc. Natl Acad. Sci. USA 103, 10544-10551 (2006).
129. Sung MH, Bagain L, Chen Z et al. Dynamic effect of bortezomib on nuclear factor-B activity and gene expression in tumor cells. Mol. Pharmacol. 74, 1215-1222 (2008).
130. Mancuso C, Scapagini G, Currò D et al. Mitochondrial dysfunction, free radical generation and cellular stress response in neurodegenerative disorders. Front. Biosci. 12, 1107-1123 (2007).